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'e COVID-19 global epidemic poses this generation’s biggest worldwide public health challenge probably since the 1918
influenza epidemic. Recent reports on two new variants have triggered a dramatic upsurge in research to understand the
pandemic, primarily focussing on the virology, triggers, clinical characteristics, and diagnostic tests including the prevention and
management of the novel coronavirus. Whilst such studies are important in managing the present medical emergency, there is a
need for further work to include interdependencies between the epidemic and other illnesses.'is will help in developing effective
approaches to treat and manage associated diseases in both the short and the long term. In this regard, people living with cancer
are a subgroup that is highly vulnerable to respiratory infections and acute pneumonitis similar to the one caused by the COVID-
19 virus. 'is is because the state of their immunity is compromised due to malignancy and the adverse effects of anticancer
treatments. With annual cancer projections rising globally and an estimated 70 percent of all cancer-related deaths occurring in
low- and middle-income countries, the patient population with impaired immune systems that could be adversely impacted by
COVID-19 is only anticipated to rise. In this review, we delve into the challenges and health risks facing cancer patients and cancer
treatment in the COVID-19 context, with suggestions into viable measures which can be taken to minimize exposure to the risk of
contracting COVID-19 for this vulnerable subgroup. New mutations and the prospects offered by vaccines development and how
they relate to this class of patients are also discussed.
1. Introduction
'ere has been a recent report of mutated variants of the
SARS-CoV-2, the virus responsible for causing COVID-19
[1]. Since the long-term effects of the virus still remain
largely unknown, this has aroused concern and anxiety on
the possible impacts of these viral changes. Not long ago,
reports of two different SARS-CoV-2 variants emerged from
the WHO authorities and they were detected in the United
Kingdom and Northern Ireland. 'ey were named VOC
202012/01, and the other, a variant from South Africa, re-
ferred to as 501Y.V2 [2]. Although no change in disease
severity has been reported for the VOC 202012/01 variant,
there are reports of increased transmissibility compared to
SARS-CoV-2 [2]. 'is further complicates the already
complicated situation in that it will require further research
to understand the new variants, yet the year-old SARS-CoV-
2 is still under study.
'e new year 2021 came with high expectations that the
vaccination campaigns taking place worldwide will arrest the
current epidemiological situation arising from the second
wave of the virus. However, since high numbers of new cases
and deaths continue to hit new records, this calls for even
stricter adherence to safety measures to reduce infections
and deaths. Unfortunately, at the pace in which the vaccine is
being procured and distributed by the most affected
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'e COVID-19 outbreak was formally declared a public
health problem of global significance by the World Health
Organization (WHO) on 30 January 2020 [3]. 'e advent of
the SARS-CoV-2 virus responsible for the COVID-19 after
the 2002 extreme acute respiratory coronavirus syndrome
(SARS-CoV) and the 2012 Middle East respiratory coro-
navirus syndrome (MERS-CoV) represented the third ad-
vent in the twenty-first century of a remarkably infectious
and large-scale coronavirus outbreak into modern civili-
zation [4–7].
A few studies have indicated that COVID-19mortality in
elderly people and in situations with other significant
comorbidities such as cancer is relatively higher [8–11].
Cancer patients, especially those with cancer of the lungs,
pose a higher risk of COVID-19-related respiratory disor-
ders [12–14]. Furthermore, the application of chemothera-
peutic agents may have a detrimental effect on the patients’
immunity, and therefore, it will be prudent to consider the
systemic anticancer treatment (SACT) risks associated with
COVID-19 [15, 16]. 'is risk may be determined by a
number of variables such as age as well as the frequency of
hospital follow-up visits which raise the risk of exposure
[14]. Epidemiology statistics collected from China estab-
lished that patients of advanced age were more severely
impacted by the disease [17].
Prior to December 2019, six strains of coronaviruses
were known to infect humans. 'ey included two ex-
tremely infectious types, SARS-CoV and Middle East
coronavirus respiratory syndrome (MERS-CoV), caus-
ing SARS and MERS, respectively [7, 8, 11, 18]. Four
more types of coronaviruses involving pulmonary dis-
eases varying from auto-resolving cold to extreme
SARS-CoV pneumonia originated in China in 2002
triggering an outbreak that affected over 8,000 people
with nearly 800 deaths [9, 19]. MERS-CoV eventually
appeared in the Middle East, triggering a recurrent
outbreak between 2012 and 2019; however, it affected
fewer people, about 2,500 people with less than 1000
fatalities [3, 20–22].
As with other coronaviruses, COVID-19 predomi-
nantly triggers infection in the respiratory system. While
COVID-19 fatalities are fewer compared to those for pa-
tients infected with SARS-CoV or MERS-CoV (Singhal,
2020), COVID-19 is more transmittable, with every new
case estimated to generate an average of 2.7 new secondary
cases. In the COVID-19 epidemic, patients with cancer are
deemed a particularly susceptible category [23, 24]. Owing
to the COVID-19 pandemic, the healthcare system faces
the challenge of reorganization, for not only managing the
[1] pandemic effectively but also simultaneously tracking
other diseases that require sustained follow-ups on treat-
ment [25].
Reports have indicated that postponements and dis-
ruptions are related to disease development and augmented
mortality among patients with thoracic, gynaecological, and
head-and-neck cancers [26]. 'is requires an optimum
balance on treatment and deferrals to mitigate COVID-19
exposure [26, 27]. With these in mind, it has been suggested
that clinical decisions should be deliberated on a case-by-
case basis to ensure that the benefit gained from sustained
cancer treatments are more than the hazards of contracting
COVID-19 [28].
While COVID-19 in the population at large is known to
have a fairly low mortality rate of 2 to 3 percent [29], cancer
patients suffering from COVID-19 not only have a nearly 3-
fold rise in mortality rates compared to COVID-19 patients
without cancer but also appear to have significantly higher
adverse effects once affected by the disease [19]. Cancer
patients have also a 10-fold greater risk of nosocomial
COVID-19 attacks compared to cancer-free ones [30, 31].
All in all, these results indicate that cancer patients in the
current COVID-19 pandemic era are a far more vulnerable
subgroup.
Towards the end of the year 2020 and in the beginning
of 2021, the COVID-19 virus gave the world another shock
through the discovery of newmutation strains. Towards the
end of September 2020, a variant called B.1.1.7 with a large
number of mutations was detected and identified in the
United Kingdom which transmits easily and more rapidly
and is suspected to carry a higher risk of death [2]. 'e
same variant was identified in the United States in De-
cember of the same year [32]. Another variant called
B.1.351 emerged in South Africa in October 2020 and the
same variant was reported in the US at the end of January
2021 [33]. In Brazil, another variant known as P.1 was
detected in early January 2021 and in the US towards the
end of January 2021 [34].
Because these variants are found to spread more rapidly,
this may lead to increased cases of COVID-19 which will
definitely add more stress on healthcare systems, leading to
increased hospital visits and admissions and possibly a
greater number of deaths.
1.1. SARS-CoV-2: Virology and Drug Targets. Unlike the
SARS-CoV and theMERS-CoV,most SARS-CoV-2 fatalities
shocked the medical fraternity by triggering multiorgan
failure syndrome instead of a respiratory dysfunction [35].
'is may be attributed to the widespread proliferation of
angiotensin-converting enzyme 2 (ACE-2) which is the
functioning receptor for SARS-CoV-2 into various organs
[36–38]. 'e virus is a single-stranded RNA encased strain
which targets cells via structural protein spikes (S protein)
that attaches themselves to the angiotensin-converting en-
zyme 2 (ACE2) receptor [37, 39], as indicated in Figures 1(a)
and 1(b).
'e virus then uses these host-cell receptor binding sites
and endosomes to enter cells [38].'e viral polyproteins that
express the replicase-transcriptase complex are synthesized
once the virus enters the cell [41, 42]. 'e virus produces
RNA using its RNA-dependent polymerase. Functional
proteins are synthesized, culminating in viral particles as-
sembly and final release [43, 44].'ese stages in the life cycle
of the virus may offer possible drug treatment targets.
Possible targets include nonstructural proteins having
similar homology to other novel coronaviruses [45–47].
Other targets involve pathways for viral entry and immune
modulation.
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Studies have shown that the magnitude of patients in-
fected with SARS-CoV-2 virus is significantly influenced by
the type of cancer [48, 49]. Patients with haematological
cancer have the highest degree of severity and death across
all cancer patients followed by lung cancer [12, 50]. Of
concern, too, is the impact that coronavirus epidemic might
have on the medication supplies as the epidemic disrupts the
pharmaceutical production and distribution processes in
China, the second-largest exporter of drugs and biologics
[51, 52].
Haematological cancer patients including patients with
leukaemia, myeloma, and lymphoma are expected to have a
more weakened immunity than patients with solid tumours
where the cancer is localized [48, 53]. 'ese patients have
been shown to have a rapidly deteriorating clinical course
once infected with COVID-19. 'is is due to the fact that
cancerous or ineffective immune cells, lymphocytes, or white
blood cells generally cannot function optimally leading to a
much-lowered immunity in haematological malignancies,
leading to more severe outcomes. 'e total lymphocyte
count and neutrophil-to-lymphocyte ratio (NLR) have been
evaluated and can be regarded as one of the indicators of the
status of immunity levels since lymphocytes are necessary
for defence and protection against viruses and cancers [11].
(a)
(b)
Figure 1: (a) Structure of SARS-CoV-2 and (b) virology and drug targets: viral lifecycle and potential drug targets (adapted from [40]).
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Both lymphocyte levels and the NLR have been shown to be
significant prognostic factors in patients with cancers or
virus infections [18].
Figure 2 shows that the most prevalent cancer is lung
cancer. 'is has a direct relationship with COVID-19 which
is a respiratory disease affecting the lungs.
As shown in Figure 3, with an estimated rise in lung
cancer as years go by, respiratory diseases will become more
and more significant requiring thorough studies into the
comanagement for the diseases.
'e stage of cancer treatment plays an important role in
mortality and morbidity risk for COVID-19 patients. 'e
type of treatment administered influences the enormity and
fatality in cancer patients once they contract COVID-19
[11, 54]. In the recent past, immunotherapy has taken on a
very significant role in the treatment of tumours by inter-
fering with cancer cells’ immune-escape routes [55]. Yet new
research has shown that immunotherapy patients have the
greatest mortality risk and the greatest seriousness of illness
compared to cancer patients treated with other therapies, a
somewhat surprising result [53, 56]. Acute respiratory
distress syndrome (ARDS) caused by cytokine storm is
reported to be the major cause of death of COVID-19-in-
fected patients, according to pathological reports [3, 57, 58].
In this context, immunotherapy may induce the production
of large quantities of cytokines, which could be noxious to
healthy cells, which include lung epithelial cells, thus giving
rise to a more serious illness. Both postoperative cancer
patients and those with developed lung cancer have been
shown to have lower lymphocyte counts than healthy people
[59]. In immune-compromised patients, unchecked virus
infection can trigger significant cell damage and induce
T-cell fatigue and even cytokine storms which are typical
causes for critical conditions [60].
COVID-19 patients with both active treatment and cancer
history have a higher risk of developing serious complications
compared to noncancerous COVID-19 patients [61]. 'is
suggests that the immunity of cancer survivors remains
compromised over a period of time. In comparison, patients
who have undergone chemotherapy or similar operation in
the near past have a statistically greater chance of developing
medically serious complications (75 percent) unlike those
who have not undertaken these procedures [62].
2. Methodology
'e main objective of this review was to highlight the
challenges of cancer care in the era of COVID-19 and the
possible mitigations in form of practical suggestions which
can be implemented to protect cancer patients from ex-
posure to the SARS-CoV-2. To achieve this, a scoping
analysis was undertaken using the following five steps:
(i) Identifying a clear research objective and search
strategies
(ii) Searching the relevant scholarly publications
(iii) Screening of the articles that fitted our objectives
(iv) Extracting data
(v) Analysing, discussing, drawing conclusions, and
reporting the results
A thorough online review of the literature was conducted
for relevant publications from December 2019 to December
2020. 'e keywords “cancer” or “oncology” were used in
combination with “covid-19,” and/or “SARS-CoV-2.” 'e
search was conducted in Google Scholar, Google search,
PubMed bioRxiv, medRxiv, and ChemRxiv. A total of 126
publications were retrieved. Relevance was determined by
the use of Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) flowchart. Selected articles of
the recovered publications were reviewed for relevance
where texts were examined and 94 suitable papers that
tarried well with the objectives of the review were selected.
An analysis of cited references appearing in some of the
selected papers was also carried out.
'e methodology is summarized in the PRISMA flow-
chart using the layout appearing in the PRISMA website as
shown in Figure 4.
2.1. COVID-19 and Cancer Management/Care. Studies
conducted in China showed that cancer patients, mainly
those who lately had received chemotherapy or surgery, were
at greater risk of negative consequences subsequent to
SARS-CoV-2 infection. Investigations of 3,920 patients
pointed out the greatest mortality in patients who had
undergone treatment in the preceding 1–3 months. Ratios
were maximum in those who had undergone chemo- or
immunotherapy in a span of 2 weeks of SARS-CoV-2 cases.
'e International Severe Acute Respiratory and Emerging
Infections Consortium, (ISARIC)-4C COVID-19 Clinical
Information Network (CO-CIN), based in the United
Kingdom, is a collaborative data collection network from
hospital in-patients with confirmed or clinically probable
SARS-CoV-2 cases. Data obtained from 20,133 participants
already hospitalised from SARS-CoV-2 infections proposed
that cancer was a major issue linked to SARS-CoV-2 deaths.
During the initial studies on cancer-specific cases, 1,797
(8.6%) of the patients were found to have malignant neo-
plasm, with a mortality rate of 35%. Later updated data
pointed out cancer as a risk issue for mortality in all age
groups, with a mortality rate of 40.5%. 'e study included
participants from over 70 centers across the United King-
dom and surveyed 800 participants with cancer having
received treatment in a span of 12 months. 'e study re-
ported a mortality rate of 28% in a population of symp-
tomatic patients in secondary care. 'is early analysis
reported a 76% ratio of patients who were on active treat-
ment 4 weeks prior to SARS-CoV-2 confirmation and
identified age, male gender, and comorbidities as risk factors
for mortality. A study on 351 patients by Dutch Oncology
and COVID-19 consortium on solid organ and haemato-
logical malignancies, with serological or radiological con-
firmation of SARS-CoV-2 infection, reported a rate of
32.3%, with age >65 years, male gender, previous/active
haematological or lung cancer cases pointed out as risk
factors of mortality.
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Another investigation carried out in 2020 on 357 par-
ticipants from 23 Swiss centers showed that 57% of the
participants who had undergone anticancer therapy in a
span of 90 days subsequent to being diagnosed with SARS-
CoV-2 had a mortality rate of 18%.'is study correlated age
and cancer treatment to worse outcomes.
In 2018, cancer was accountable for approximately 9.6
million fatalities and is estimated to be liable for 1 in 6
fatalities worldwide in 2020 [63]. Cancer patients are more
vulnerable to illness than cancer-free people owing to a
chronic immunosuppressive condition triggered by metas-
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Figure 3: Estimated past and future trends in total cases per year (breast and lung).
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surgical procedures [49, 53, 62, 63]. According to a recently
released Chinese study, the chance for patients with cancer
to experience extreme outcomes in terms of critical care
admission, intrusive breathing, or death, relative to people
without cancer, was 39 percent versus 8 percent [3, 61]. 'e
age factor plays out in that most cancers occur at a later age
affecting the older population to a larger extent, further
compromising this age group with an already compromised
immunity. Reports indicate that, in the United States, 80
percent of all cases are found in people 65 years of age and
above, with similar observations made in studies conducted
in Wuhan, China [64].
COVID-19 pandemic has posed a major challenge in
almost every hospital especially in areas requiring ICU
support, particularly the surgical units and others requiring
respiratory aiding equipment. 'e presence of COVID-19-
infected patients in the ICU typically creates an extra burden
which limits the capacity of non-COVID-19 patients in the
ICU to receive optimum treatment [65].
Hospital admissions and repeated hospital visits have
been classified as possible hazard factors for the infection of
COVID-19 [66]. Moreover, while research concludes that
cancer patients have worse COVID-19 outcomes, it also
indicates that the mean age of such patients (63.1 years) is
slightly higher compared to those without cancer (48.7
years), indicating that advanced age was correlated with
worse COVID-19 results [9, 11, 62, 66].
'e World Health Organization (WHO) declared
COVID-19 an international public health crisis and raised its
risk assessment from “high” to “very high” with a similar
declaration made in Korea [63, 67, 68]. Taking into account
that there are high and still rising numbers of infected
persons with SARS-CoV-2, cancer should not be ignored as
a coexisting illness.'is is due to the fact that cancer patients
are frequently recalled to hospitals for treatment and disease
monitoring, and medical procedures such as chemotherapy
or radiation therapy are immune suppressants, raising the
risk of contracting COVID-19. Similarly, the risks faced by
cancer patients should equally be raised to very high.
2.2. COVID-19 Vaccines and Cancer Patients. COVID-19
vaccines currently in use are anticipated to offer protection
against the virus and the new variants [69]. 'ese vaccines
have been designed to provoke a wide-ranging immune
response specifically invoking the cells to produce a harmless
copy of a virus’s spike protein, and, therefore, the mutated
variants will not render the vaccines ineffective [70].
Wide-scale production and distribution of vaccines still
remains the most critical way of fighting the variants and
protecting people who might be exposed. 'is in turn re-
duces the spread rates and might be effective in the long run
in the elimination of the virus and its variants [71]. 'e
current priority of vaccination for “high-risk” groups like
doctors and frontline caregivers is also a good move in
minimizing the chances of transmission and spread [72].
'e more the number of people who access the vaccines, the
less the transmission, and this will result in fewer mutations
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[71]. While this is the case, we still need to take all pre-
cautions to arrest the spreading of the virus and thereby
avert possible mutations that may diminish the effectiveness
of present vaccines.
For cancer patients, the key worry about the vaccines is
not their safety, but about how effective they will be con-
sidering the weakened immunity for people with cancer [59].
As discussed above, treatments like chemotherapy, radio-
therapy, or immunotherapy affect the immune system which
may compromise the efficacy of the vaccines [73]. However,
most conclusions on the effects of COVID-19 vaccines on
cancer patients are subjective because initial tests with these
vaccines did not include people already undergoing treat-
ment with immunosuppressant drugs like chemotherapy
drugs, or people with already weakened immune systems.
'e initial focus was on people with strong and vibrant
immune systems [4]. 'erefore, there is no conclusive data
on the efficacy of these vaccines for these groups of people.
'e lack of conclusive information does not imply that
these vaccines will not work on this class of people. We
might however expect that they might not be as effective in
people with weakened immune systems as in people with
vibrant immune systems [74]. Because of the higher risk this
class of people face in terms of being more adversely affected
by the COVID-19 variants, it will be best for them to get
vaccinated [59]. It can be concluded that getting some
protection from the vaccine is better than not having any
protection [59].
As with many new vaccines, there are health concerns
raised not only on efficacy but on adverse side effects [75].
'ese should, however, not make us suspend the exercise of
getting vaccinated.We need to utilize the tools available even
as research continues to make improvements.
3. Results and Discussion
Out of the 94 publications reviewed, 90 were journal articles
and 4 were cohort studies involving retrospective case
studies and cross-sectional analyses. All the reviewed articles
were only selected for either the relevant acronyms of
“COVID-19” or “SARS-CoV-2” and the terms “cancer” or
“oncology.”
In lieu of the COVID-19 epidemic and other future
infectious outbreaks which may have direct impacts on
cancer patients, deliberate postponement of adjuvant che-
motherapy or surgical procedures may be considered in mild
cases. Since the immunity of cancer survivors remains
progressively compromised over a period of time, the rel-
evant authorities should freely provide effective personal
protective equipment for cancer victims or survivors who
may need to visit hospitals [76]. When cancer patients get
infected with COVID-19, more rigorous monitoring or
treatment regimens should be urgently considered, partic-
ularly in the older patients and those with other comor-
bidities [77]. Initiatives that could make it possible to
manage cancer patients at home must also be considered.
'ese can be achieved through telecare and video calls
with the physicians to reduce hospital visits, as well as
replacing invasive treatments with oral medication where
practicable [78]. 'is will be an effective method in pro-
viding noncontact follow-ups on management and care to
cancer patients [79]. Patients who find themselves in an
affected environment should be immediately isolated. Re-
sources and equipment to enable intravenous anticancer
drugs may be delivered at home where applicable. Che-
motherapy dosage may also be adjusted and radiotherapy
hypofractionated as an additional measure to reduce hos-
pital visits [80]. Studies conducted on radiotherapy on
cervical cancer during the COVID-19 era suggest that
hypofractionation may be more relevant in this era due to
the experienced pressure on medicare facilities occasioned
by the COVID-19 pandemic [81].
Furthermore, at the recommendation of the prescribing
oncologist, certain patients with slowly developing meta-
static tumours may be granted brief gaps in their care, with
condition monitoring extended to prevent hospital admis-
sions [82]. However, despite these steps, certain cancer
patients may continue with hospital admission for routine
treatment or radiotherapy.
In order to ensure that such patients do not show any
complications consistent with COVID-19 before being ad-
mitted to oncology or radiotherapy wards, it would be
prudent for caregivers to make regular calls to those
scheduled for admission, just to know their status [83, 84].
'e greatest threat for cancer patients in this pandemic is the
difficulty or inability to obtain requisite healthcare services
in terms of getting to the hospital and receiving regular
follow-ups [83]. 'is is mainly in part due to movement
restrictions and imposed isolation and quarantine advi-
sories. Country-specific strategies will need to be adopted in
the future where countries will have to reorganize the
healthcare systems for both cancer treatment and other
major comorbidities [85].
Decisions as to whether or not to postpone cancer
therapy for people already infected with COVID-19 should
be taken on a case-by-case basis [86]. 'is may depend on
the threat to the individual and their prevailing conditions as
delays may contribute to worsening of cancer and eventually
to worse outcomes [87]. If admission to the hospital is
considered unavoidable, admissions should be referred to
the departments concerned in fighting COVID-19 so that
facilities for oncology and radiation therapy remain free of
COVID-19 [88]. 'is is because cancer wards might not be
fitted with the requisite quarantine facilities necessary in
COVID-19 situations. Furthermore, outpatient facilities
should implement demarcation measures (e.g., minimum
seating space to maintain social distance, movable walls,
patient and staff wearing masks) to protect patients with
cancer.
4. Conclusion
In conclusion, this study shows that patients with cancer
and/or cancer-related complications are at an obvious
higher risk of worse outcomes subsequent to SARS-CoV-2
infection in comparison to cancer-free patients, where
mortality rates have been shown to range from 13 to 40.5%.
Factors like age and preexisting comorbidities have also been
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associated with worse outcomes in patients with cancer who
acquire SARS-CoV-2.
We believe that this short but comprehensive review will
definitely be of help to decision-makers, to assist in giving
direction in the management of cancer patients impacted by
the current COVID-19 outbreak. 'e same procedures are
also applicable to other patients who might require constant
hospital visits thereby raising their risk of contracting
COVID-19. 'is will be most appropriate especially for
African and other developing countries, whose healthcare
systems not only are strained but also lack most of the
intensive care facilities needed in COVID-19 situations.
Adapting telecare and other home-based consultations and
follow-ups will relieve our healthcare facilities of both hu-
man-to-human interactions and reduce the associated risks
of patients carrying the virus home and also leave the
medical personnel available to address the very critical cases.
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